LINNIK MATTHEW (US)
VALENZUELA FRANCISCO (US)
BRENNAN SEAMUS PATRICK (US)
LINNIK MATTHEW DAVID (US)
VALENZUELA FRANCISCO ALCIDES (US)
WO2018232088A1 | 2018-12-20 |
WAN LI ET AL: "Optimizing Size and Copy Number For PEG-fMLF (N-Formyl-methionyl-leucyl-phenylalanine) Nanocarrier Uptake by Macrophages", BIOCONJUGATE CHEMISTRY, vol. 19, no. 1, 20 December 2007 (2007-12-20), pages 28 - 38, XP055956966, ISSN: 1043-1802, DOI: 10.1021/bc070066k
M MIYAZAKI ET AL: "Dimeric chemotactic peptides discriminate between chemotaxis and superoxide production of human neutrophils", JOURNAL OF BIOCHEMISTRY, vol. 117, no. 3, March 1995 (1995-03-01), JAPAN, pages 489 - 494, XP055393042, Retrieved from the Internet
RYAKHOVSKII V V ET AL: "Synthesis of chemotaxic tripeptide analogs containing L- and D-(S-trifluoromethyl)-homocysteine and having hypotensive activity", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 26, February 1992 (1992-02-01), pages 157 - 162, XP055956330, Retrieved from the Internet
HOUSTON M E ET AL: "Syntheses of and chemotactic responses elicited by fmet-leu-phe analogs containing difluoro- and trifluoromethionine", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 23, 2 December 1997 (1997-12-02), pages 3007 - 3012, XP004136574, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(97)10134-2
JAIME-RAMIREZ ALENA C. ET AL: "NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines", CANCER IMMUNOLOGY RESEARCH, vol. 4, no. 4, April 2016 (2016-04-01), pages 323 - 336, XP055957366, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-15-0168
HE HQYE RD, MOLECULES, vol. 22, no. 3, 13 March 2017 (2017-03-13), pages E455
HWANG TL ET AL., ORG BIOMOL CHEM., vol. 1, no. 22, 14 June 2013 (2013-06-14), pages 3742 - 55
CAVICCHIONI G ET AL., BIOORG CHEM, vol. 34, no. 5, October 2006 (2006-10-01), pages 298 - 318
HIGGINS JD ET AL., J MED CHEM., vol. 39, no. 5, 1 March 1996 (1996-03-01), pages 1013 - 5
VERGELLI C ET AL., DRUG DEV RES, vol. 78, no. l, February 2017 (2017-02-01), pages 49 - 62
KIRPOTINA LN ET AL., MOL PHARMACOL., vol. 77, no. 2, February 2010 (2010-02-01), pages 159 - 70
CILIBRIZZI A ET AL., J MED CHEM., vol. 52, no. 16, 27 August 2009 (2009-08-27), pages 5044 - 57
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH
CHOTHIA CLESK AM, J MOL BIOL, vol. 196, 1987, pages 901 - 917
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883
LEFRANC ET AL., DEV COMP IMMUNOL, vol. 27, 2003, pages 55 - 77
HONEGGER APLUCKTHUN A, J MOL BIOL, vol. 309, 2001, pages 657 - 670
MARIE-PAULE LEFRANCGERARD LEFRANC: "The Immunoglobulin Factsbook", 2001, ACADEMIC PRESS
HOUSTON ET AL., BIORG & MEDIC. CHEM. LETT, vol. 7, no. 23, 1997, pages 3007 - 3012
THOMAS ET AL., LANCET ONCOL, vol. 17, no. 6, June 2016 (2016-06-01), pages e254 - 62
DIAMANTISBANERJI, BRIT. JOURN. CANCER, vol. 1, no. 14, 2016, pages 362 - 367
CLAIMS We claim: 1. A conjugated antibody or antigen-binding fragment thereof comprising an antibody or an antigen-binding fragment thereof that is conjugated to a peptide comprising an N- formyl-halogenated methionine residue at the N-terminus of the peptide. 2. The conjugated antibody of claim 1, wherein the N-formyl-halogenated methionine residue is N-formyl-trifluorinated methionine. 3. The conjugated antibody of claim 1, wherein the antibody is conjugated to the peptide via a linker. 4. The conjugated antibody of claim 3, wherein the conjugated antibody has a formula represented as: 5. The conjugated antibody of claim 3, wherein the peptide comprises a C-terminal glutamic acid residue and the peptide is conjugated to the linker via an amide bond formed between the gamma carboxyl group of the glutamic acid and an amino group of the linker. 6. The conjugated antibody of claim 3, wherein the peptide comprises a C-terminal lysine residue and the peptide is conjugated to the linker via an amide bond formed between the epsilon amino group of the lysine and a carboxyl group of the linker. 7. The conjugated antibody of claim 3, wherein the conjugated antibody has a formula represented as: 8. The conjugated antibody of claim 1, wherein the peptide comprises 2-10 amino acids. 9. The conjugated antibody of claim 1, wherein the peptide comprises 2-10 amino acids selected from D-amino acids. 10. The conjugated antibody of claim 1, wherein the peptide comprises 2-10 amino acids selected from homologues of amino acids lacking one or more methylene groups between the α-carbon and the side chain or homologous of amino acids possessing an additional methylene group between the α -carbon and the side chain. 11. The conjugated antibody of claim 10, wherein the peptide comprises 2-10 amino acids selected from homologues of amino acids lacking one or more methylene groups between the α-carbon and the side chain. 12. The conjugated antibody of claim 1, wherein the peptide comprises 2-10 amino acids selected from homo-amino acids. 13. The conjugated antibody of claim 1, wherein the peptide comprises 2-10 amino acids selected from bishomo-amino acids. 14. The conjugated antibody of claim 1, wherein the peptide comprises 2-10 amino acids selected from alkylated amino acids comprising an alkyl substitution on the α-carbon. 15. The conjugated antibody of claim 1, wherein the peptide comprises 2-10 amino acids selected from di-alkylated amino acids comprising a di-alkyl substitution on the α-carbon. 16, The conjugated antibody of claim 1, wherein the peptide comprises 2-10 amino acids selected from alkylated amino acids comprising an alkyl substitution on the amino group). 17. The conjugated antibody of claim 1, wherein the peptide comprises 2-10 amino acids selected from phenylalanine, tyrosine, tryptophan, histidine, proline, naphthylalanine. 18. The conjugated antibody of claim 1, wherein the peptide comprises 2-10 amino acids selected from nor-amino acids and linear core amino acids. 19. The conjugated antibody of claim 1, wherein the peptide comprises 2-10 amino acids selected from amino acids comprising a substitution selected from alkynyl, azido, thiophenyl, thienyl, , pyridyl, anthrenyl, cycloalkyl, diphenyl, furyl, and naphthyl. 20. The conjugated antibody of claim 1, wherein the peptide comprises 2-10 amino acids selected from amino acids having a formula NH2-CH2-CH2-(O-CH2-CH2)n-COOH, wherein n is selected from 1-24. 21. The conjugated antibody of claim 1, wherein the peptide comprises 2-10 amino acids selected from β-amino acids, γ-amino acids, δ-amino acids, ε-amino acids, and ζ-amino acids. 22. The conjugated antibody of claim 1, wherein the peptide comprises 2-10 amino acids selected from cycloamino acids. 23. The conjugated antibody of claim 1, wherein the peptide comprises an amino- protecting group. 24. The conjugated antibody of claim 3, wherein the linker comprises a spacer arm having a length of about 10-50 angstroms. 25. The conjugated antibody of claim 3, wherein the linker comprises a spacer arm and the linker has a formula selected from: 26. The conjugated antibody of claim 25, wherein the linker has a formula selected from where n is an integer selected from 3-24. 27. The conjugated antibody of claim 24, wherein the spacer arm is a peptide sequence comprising amino acids selected from glycine, serine, and alanine. 28. The conjugated antibody of claim 3, wherein the linker comprises a polyethylene glycol (Peg) moiety (i.e., (-O-CH2-CH2)1-24). 29. The conjugated antibody of claim 3, wherein the linker comprises a split polyethylene glycol moiety represented as -((Peg)1-24)-(AA)1-2-((Peg)1-24)-, wherein AA is Glutamic acid residue connected through its side-chain gamma carboxyl group or Lysine residue connected through its side-chain epsilon amino group. 30. The conjugated antibody of claim 3, wherein the peptide-linker has a formula selected from: frm-M(CF3)-Ile-Phe-Leu-Peg12-NH-(CH2)2-Y, frm-M(CF3)-Leu-Phe-Peg12-NH-(CH2)2-Y, frm-M(CF3)-Dpg-2Nal-αMeF-Nle-γE-Peg12-NH-(CH2)2-Y, frm-M(CF3)-Dpg-2Nal-αMeF-D-Nle-γE-Peg12-NH-(CH2)2-Y, frm-M(CF3)-Dpg-2Nal-αMeF-Nle-γE-Peg6-γE-γE-Peg6-NH-(CH2)2-Y, frm-M(CF3)-Dpg-2Nal-αMeF-Nle-γE-Peg6-εK-εK-Peg6-NH-(CH2)2-Y, frm-M(CF3)-Dpg-2Nal-αMeF-D-Nle-γE-Peg12-NH-(CH2)2-Y, frm-M(CF3)-Dpg-2Nal-αMeF-γE-Peg12-NH-(CH2)2-Y, and frm-M(CF3)-Dpg-4Pal-αMeF-Nle-γE-Peg12-NH-(CH2)2-Y, wherein Y comprises an amino group or a cysteine-reactive moiety for conjugating the peptide- linker to the antibody. 31 The conjugated antibody of claim 30, wherein the cysteine-reactive moiety is selected from maleimide, maleimide-diaminopropionic, iodoacetamide, or vinyl sulfone. 32. The conjugated antibody of claim 3, wherein the linker comprises a maleimide moiety and the linker is conjugated to the antibody via a thioether bond formed between the maleimide moiety and a cysteine residue of the antibody. 33. The conjugated antibody of claim 32, wherein the antibody comprises an IgG heavy chain constant region and light chain region wherein said cysteine residue is selected from residue 124 of the CH1 domain, residue 378 of the CH3 domain, or both of residue 124 of the CH1 domain and residue 378 of the CH3 domain. 34. The conjugated antibody of claim 1, wherein the antibody is a human antibody, a chimeric or hybrid antibody, or a humanized antibody. 35. The conjugated antibody of claim 1, wherein the antibody comprises an IgG heavy chain constant region selected from human IgG1 isotype or human IgG4 isotype. 36. The conjugated antibody of claim 35, wherein the antibody comprises an IgG heavy chain constant region comprising an isoleucine substituted at residue 247, a glutamic acid substituted at residue 332, or both of an isoleucine substituted at residue 247 and a glutamic acid substituted at residue 332, with numbering based on EU Index Numbering. 37. The conjugated antibody of claim 36, wherein the antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 52, 53, 54, 55, 56, or 57. 38. The conjugated antibody of claim 1, wherein the antibody is a monoclonal antibody. 39. The conjugated antibody of claim 1, wherein the antibody is a bispecific antibody. 40. The conjugated antibody of claim 1, wherein the antibody binds to an antigen selected from HER2, PSMA, TROP2, MUC-1, Nectin 4, LIV-1, mesothelin, MUC-16, folate receptor-R1, CEACAM5, GPNMB, CD56, STEAP1, ENPP3, guanylyl cyclase C, SLC44A4, NaPi2b, CD70, CA9 carbonic anhydrase, 5T4, SC-16, tissue factor, P-Cadherin, Fibronectin Extra-domain B, endothelin receptor ETB, VEGFR2, Tenascin c, periostin, DLL3, EGFR, CD30, CD22, CD79b, CD19, CD138, CD74, CD37, CD33, and CD98. 41. The conjugated antibody of claim 1, wherein the antibody comprises one or more of an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of an antibody selected from T-DM1, ARX788, SYD985, MLN2704, PSMA-ADC, TACSTD2, sacituzumab govitecan, (IMMU-132), SAR-566658, enfortumab vedotin (ASG-22M6E), ASC-22CE, ZIP6, SGN-LIV1A, DMOT4039A, anetumab ravtansine (BAY-94–9343), BMS-986148, sofituzumab vedotin, mirvetuximab soravtansine (IMGN-853), vintafolide, labetuzumab SN-38, glembatumumab vedotin, lorvotuzumab mertansine (IMGN-901), vandortuzumab vedotin (RG- 7450), AGS-16M8F, indusatumab vedotin (MLN-0264), ASG-5ME, lifastuzumab vedotin, TNFSF7, DNIB0600A, AMG-172, MDX-1243, vorsetuzumab mafodotin (SGN-75), BAY79– 4620, TPBG, PF 06263507, SLTRK6 (ASG-15ME), anti-Fyn3, SC16LD6.5, HuMax-TF-ADC (TF-011-MMAE), PCA062, Human mAb L19, Human mAb F8, RG-7636, anti-VEGFR-2ScFv- As2O3-stealth nanoparticles, anti-TnC-A1 antibody SIP(F16), anti-periostin antibody, rovalpituzumab soravtansine, ABT-414, IMGN289 AMG-595, brentuximab vedotin, iratumumab MDX-060, inotuzumab ozogamicin (CMC-544), pinatuzumab vedotin, epratuzumab SN38, polatuzumab vedotin, coltuximab ravtansine, SAR-3419, SGN-CD19A, indatuximab ravtansine, milatuzumab doxorubicin, IMGN-529, gemtuzumab ozogamicin, IMGN779, SGN CD33 A, and IGN523. 42. A pharmaceutical composition comprising the conjugated antibody of claim 1 and one or more pharmaceutically acceptable carriers, diluents, or excipients. 43. A method of treating a solid cancer or liquid tumor comprising administering to a patient in need thereof an effective amount of a conjugated antibody, as recited in claim 1, or a pharmaceutical composition thereof, as recited in claim 42. 44. The method of claim 43 for treating breast cancer, lung cancer, prostate cancer, skin cancer, colorectal cancer, bladder cancer, kidney cancer, liver cancer, thyroid cancer, endometrial cancer, muscle cancer, bone cancer, mesothelial cancer, vascular cancer, fibrous cancer, leukemia, or lymphoma. 45. The conjugated antibody of claim 1 for use in a therapy. 46. The conjugated antibody of claim 1 for use in the treatment of a solid cancer or liquid tumor. 47. The conjugated antibody of claim 46 for use in the treatment of breast cancer, lung cancer, prostate cancer, skin cancer, colorectal cancer, bladder cancer, kidney cancer, liver cancer, thyroid cancer, endometrial cancer, muscle cancer, bone cancer, mesothelial cancer, vascular cancer, fibrous cancer, leukemia, or lymphoma. 48. Use of the antibody of claim 1 for manufacturing a medicament for the treatment of a solid cancer or liquid tumor. 49. The use of claim 48, wherein the solid cancer or liquid tumor is selected from breast cancer, lung cancer, prostate cancer, skin cancer, colorectal cancer, bladder cancer, kidney cancer, liver cancer, thyroid cancer, endometrial cancer, muscle cancer, bone cancer, mesothelial cancer, vascular cancer, fibrous cancer, leukemia, or lymphoma. 50. A method for stimulating reactive oxygen species (ROS) production in a neutrophil, the method comprising contacting the neutrophil with the conjugated antibody of claim 1 under conditions whereby the conjugated antibody stimulates ROS production in the neutrophil. 51. The method of claim 48, wherein the linker of the conjugated antibody comprises a polyethylene glycol spacer comprising at least 12 monomers. 52. A compound having a formula R-P1-P2-P3-NH-(CH2CH2O)n-CH2CH2-Y or a salt thereof, wherein: R is a HC(=O)- ; P1 is Met(C(halogen)m where m is 1-3; P2 is 1-6 proteinogenic or non-proteinogenic amino acids bonded to P1 and to each other via peptide bonds; P3 is an amino acid comprising a side chain which comprises a -COOH moiety or a -NH2 moiety and P3 is bonded to P2 via a peptide bond; n is an integer selected from 3-24; and Y comprises amino or a cysteine reactive moiety. 53. A compound having a formula R-P1-P2-P3-NH-(CH2CH2O)n-CH2CH2-Y or a salt thereof, wherein: R is a HC(=O)- ; P1 is Met or Met(C(halogen)m where m is 1-3; P2 is 1-6 proteinogenic or non-proteinogenic amino acids bonded to P1 and to each other via peptide bonds; P3 is an amino acid comprising a side chain which comprises a -COOH moiety and P3 is bonded to P2 via a peptide bond; n is an integer selected from 3-24; and Y comprises amino or a cysteine reactive moiety. |
[0091] The components of the disclosed conjugates, i.e., the peptide, the optional linker, and the antibody or antigen-binding fragment thereof may be conjugated via bonds formed between any suitable reactive groups. In some embodiments, the peptide comprises a C-terminal glutamic acid residue and the peptide is conjugated to the linker via an amide bond formed between the gamma carboxyl group of the glutamic acid and an amino group of the linker. In other embodiments, the peptide comprises a C-terminal lysine residue and the peptide is conjugated to the linker via an amide bond formed between the epsilon amino group of the lysine and a carboxyl group of the linker. [0092] The disclosed conjugates may comprise multiple peptides, multiple linkers, and/or multiple antibodies or antigen-binding fragments thereof. In some embodiments, the conjugates comprise at least two peptides and linkers and may form a branched structure. In some embodiments, the conjugates have a formula represented as: which may be characterized as a branched structure. [0093] The peptides disclosed herein typically include an N-terminal, N-formyl, halogen- substituted methionine residue. The peptides typically comprise additional amino acids and in some embodiments, the peptides may comprise 2-50 amino acids (or 2-40, 2-30, 2-20, or 2-10 amino acids) amino acids bonded via peptide bonds formed between amino groups and carboxyl groups in the backbone or side-chains of the amino acids. Preferably, the disclosed peptides are resistant to cleavage by endopeptidases, for example, endopeptidases that are associated with neutrophils and integral membrane endopeptidases in particular. In some embodiments, the disclosed peptides are resistant to cleavage by endopeptidase 24.11 (EP 24.11; E.C.3.4.24.11, also called enkephalinase neutral endopeptidase, CALLA, CD10, or neprilysin); and/or endopeptidase 24.15 (EP 24.15; E.C.3.4.24.15) a metallopeptidase found within alveolar macrophages, monocytes, T lymphocytes, and B lymphocytes; and/or CD13/aminopeptidase N (CD13/APN); and/or BP-1/6C3/aminopeptidase A (BP-1/6C3/APA); and CD26/dipeptidyl peptidase IV (CD26/DPPIV). [0094] In some embodiments, the disclosed peptides and conjugates thereof comprise one or more non-proteinogenic amino acids including N-formyl, halogen-substituted methionine at the N-terminus and optionally one or more non-proteinogenic amino acids other than N- formyl, halogen-substituted methionine. Preferably, the non-proteinogenic amino acids and/or the bonds formed between the non-proteinogenic amino acids render the peptides resistant to cleavage by endopeptidases as disclosed herein. [0095] As would be understood in the art, non-proteinogenic amino acids are amino acids that are not coding amino acids in an organism and are not observed to be naturally present in proteins. Proteinogenic amino acids include L-amino acid forms of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. Therefore, non-proteinogenic amino acids may be defined as an amino acid (i.e., a molecule comprising a free amino group and a free carboxyl group bonded to an α-carbon atom) which is not any of L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-cysteine, L-glutamic acid, L- glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L- phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine. For example, a non-proteinogenic amino acid may have a formula, NH 2 -C(R)-COOH, wherein R is not a side chain of any of the coding, proteinogenic amino acids. [0096] In some embodiments, the disclosed peptides and conjugates thereof comprise one or more non-proteinogenic amino acids selected from D-amino acids. Suitable D-amino acids may include, but are not limited to D-amino acids of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and/or valine. [0097] In some embodiments, the disclosed peptides comprise non-proteinogenic amino acids which are homologues of coding amino acids that lack one or more methylene groups (- CH 2 -) between the α-carbon and the side chain of the amino acid. Suitable homologues for use as non-proteinogenic amino acids of the disclosed peptides and conjugates thereof may include, but are not limited to 2-aminoisobutyric acid, 2-amino-2-hydroxyacetic acid, 2α-methyl-2- hydroxy-glycine, 2-amino-2-methylbutyric acid (i.e., isovaline), methylcysteine, azetidine-2- carboxylic acid, phenylglycine, 4-hydroxyphenylglycine, 3-indolylglycine, aminomalonic acid, 2,3-diamino-3-oxopropanoic acid, 2-amino-2-(1H-imidazol-5-yl)acetic acid, ornithine, 2,4- diaminobutanoic acid, 2,3-diaminopropionic acid, and 2-amino-4- (diaminomethylideneamino)butanoic acid. [0098] In some embodiments, the disclosed peptides comprise non-proteinogenic amino acids which are homologues of coding amino acids which possess one or more additional methylene groups (-CH 2 -) between the α-carbon and the side chain (e.g., homo-amino acids possessing a single additional methylene group (-CH 2 -), bishomo-amino acids possessing two additional methylene groups (-CH 2 -CH 2 -), and the like). Suitable homologues for use as non- proteinogenic amino acids of the disclosed peptides and conjugates thereof may include, but are not limited to homo-amino acids of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine, such as homo-alanine, homo-arginine, homo-glutamine, homo-glutamic acid, homo-isoleucine, homo-leucine, homo-lysine, homo- methionine, homo-phenylalanine, homo-proline (i.e., piperidine-2-carboxylic acid), homo-serine, homo-threonine, homo-tryptophan, and homo-tyrosine. Suitable homologues for use as non- proteinogenic amino acids of the disclosed peptides and conjugates thereof may include, but are not limited to bishomo-amino acids of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. [0099] In some embodiments, the disclosed peptides comprise non-proteinogenic amino acids which are alkylated amino acids comprising an alkyl substitution (e.g., a C 1 -C 6 alkyl substitution such as methyl) on the α-carbon. Suitable alkyl-substituted amino acids may include α-carbon, alkyl substituted alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine, such as 2-methyl-serine (i.e., α-methyl-serine), 2- methyl-threonine (i.e., α-methyl-threonine), α-methyl-valine, α-methyl-leucine, 2-amino-2,3- dimethyl-pentanoic acid (i.e., α-methyl-isoleucine), α-methyl-methionine, α-methyl-cysteine, 2- methyl-proline, α-methyl-phenylalanine, α-methyl-tyrosine, α-methyl-tryptophan, 2-methyl- aspartic acid, 2-methyl-glutamic acid, 2,4-diamino-2-methyl-4-oxobutanoic acid (i.e., α-methyl- asparagine), 2,5-diamino-2-methyl-5-oxopentanoic acid (i.e., α-methyl-glutamine), α-methyl- histidine, α-methyl-lysine, and 2-methyl-arginine (i.e., α-methyl-lysine). In some embodiments, the disclosed peptides comprise non-proteinogenic amino acids which are di-alkylated amino acids comprising a di-alkyl substitution (e.g., a C 1 -C 6 di-alkyl substitution such as di-methyl) on the α-carbon. Suitable di-alkylated substituted amino acids may comprise α-carbon, di-alkyl substituted glycine, , such as di-n-propylglycine (Dpg). [00100] In some embodiments, the disclosed peptides comprise non-proteinogenic amino acids which are alkylated amino acids comprising an alkyl substitution (e.g., a C 1 -C 6 alkyl substitution such as methyl) on the amino group. Suitable N-alkylated amino acids may include N-alkylated alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine, (such as N-methyl-alanine, N-methyl-arginine, N- methyl-asparagine, N-methyl-aspartic acid, N-methyl-cysteine, N-methyl-glutamic acid, N- methyl-glutamine, N-methyl-glycine, N-methyl-histidine, N-methyl-isoleucine, N-methyl- leucine, N-methyl-lysine, N-methyl-methionine, N-methyl-phenylalanine, N-methyl-proline, N- methyl-serine, N-methyl-threonine, N-methyl-tryptophan, N-methyl-tyrosine, and N-methyl- valine). [00101] In some embodiments, the disclosed peptides comprise non-proteinogenic amino acids selected from phenylalanine, tyrosine, tryptophan, histidine, proline, naphthylalanine, which optionally include a ring substitution selected from C 1 -C 6 alkyl substitutions, halogen- substitutions, and cyano-substitutions. Suitable non-proteinogenic amino acids may include 2- fluoro-phenylalanine, 2-methyl-tyrosine, and 2-naphthylalanine. [00102] In some embodiments, the disclosed peptides comprise non-proteinogenic amino acids selected from nor-amino acids and/or linear core amino acids. Suitable nor-amino acids and/or linear core amino acids may include, but are not limited to norleucine (Nle), norvaline (Nva), 12-amino-dodecanoic acid, 8-amino-caprylic acid, 7-amino-enanthic acid, 6-amino- carpoic acid, and 5-amino-pentanoic acid. [00103] In some embodiments, the disclosed peptides comprise non-proteinogenic amino acids which are coding, proteinogenic amino acids which are substituted with a substituent. Suitable non-proteinogenic amino acids may include may alanine which is substituted with a substituent selected from alkynyl (e.g., propargylglycine), azido (e.g., 4-azido-homo-alanine), thiophenyl, thienyl, (e.g., 3-(2-thineyl)-alanine), pyridyl (e.g., 3-(4-pyridyl-alanine (4-Pal)), anthrenyl, cycloalkyl, diphenyl, furyl, and naphthyl (e.g., 2-naphthylalanine). [00104] In some embodiments, the disclosed peptides comprise non-proteinogenic amino acids comprising an ethylene-oxy moiety. Suitable non-proteinogenic amino acids may include amino acids having a formula NH 2 -CH 2 -CH 2 -(O-CH 2 -CH 2 )n-COOH, wherein n is selected from 1-24. [00105] In some embodiments, the disclosed peptides comprise non-proteinogenic amino acids which are not α -amino acids. Suitable non-α-amino acids may include β-amino acids, γ- amino acids, δ-amino acids, ε-amino acids, and ζ-amino acids (e.g., β-, γ-, δ, ε-, and ζ-amino acids of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine). [00106] In some embodiments, the disclosed peptides comprise non-proteinogenic amino acids which are cycloamino acids (e.g., cycloamino acids other than proline). Cycloamino acids are amino acids which comprise a cyclic group formed by a nitrogen atom and a carboxyl group. Suitable cycloamino acids may include, but are not limited to aziridine-2-carboxylic acid, azetidine-2-carboxylic acid, piperidine-2-carboxylic acid, azepane-2-carboxylic acid, cycloleucine, homocycloleucine, 1-piperidine-4-carboxylic acid, piperidine-3-carboxylic acid, 1- piperazineacetic acid, 4-piperidineacetic acid, and 1-piperidineacetic acid. [00107] In some embodiments, the disclosed peptides comprise proteinogenic amino acids and/or non-proteinogenic amino acids which optionally include an amino-protecting group. Suitable amino-protecting groups may include, but are not limited to allyloxycarbonyl (Alloc), 9- fluorenylmethyl carbonyl (Fmoc), t-butyl carbonyl (BOC), and benzyl carbonyl (Cbz). [00108] The disclosed peptides may be conjugated directly to an antibody or an antigen- binding fragment thereof. In other embodiments, the disclosed peptides may be conjugated indirectly to an antibody or an antigen-binding fragment thereof via a linker. In some embodiments, the linker has a selected linear length. Suitable selected lengths may include at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 angstroms or longer, or a range bounded by any of these values (such as 5-10 angstroms, 10-20 angstroms, 15-20 angstroms, 15-25 angstroms, 20-35 angstroms, 30-40 angstroms, 35-40 angstroms, 35-50 angstroms, and 40-50 angstroms). [00109] In some embodiments, the disclosed linkers have a spacer arm which may provide the linker with a selected length. For example, the disclosed linkers may have a formula represented as: [00112] Suitable spacer arms may comprise a polymeric moiety such as polyethylene glycol. [00113] In some embodiments, the linker has a formula selected from: [00116] where n is an integer selected from 3-24. [00117] As a particular embodiment, the linker may include a malemide moiety and a PEG moiety and may be referred to as a "maleimide-PEG linker" which conjugates an N-formyl- CF 3 -methionine to an antibody. Exemplary conjugates may have formulas selected from: Antibody or AntigenBinding Fragment and Antibody or Antigen-Binding Fragment . [00118] In some embodiments, the spacer arm comprises a peptide sequence of 1-20 amino acids. In some embodiments, the spacer arm is a peptide sequence comprising amino acids selected from glycine, serine, and alanine (e.g., (G4S)m where m is an integer selected from 1-5). [00119] The disclosed linkers may comprise a polyethylene glycol moiety, for example, as a spacer arm or otherwise. In some embodiments, the linker comprises a polyethylene glycol (PEG) moiety (i.e., (-O-CH2-CH2) 1-24 ). [00120] In some embodiments, the disclosed linkers may comprise two or more PEG moieties that are split by a non-PEG moiety such as amino acid moieties. In some embodiments, the disclosed linkers comprise a split polyethylene glycol moiety represented as -((PEG) 1-24 )- (AA) 1-2 -((PEG) 1-24 )-, wherein AA is Glutamic acid bonded via gamma amino acylation or Lysine bonded via epsilon amino acylation. [00121] Suitable peptide-linkers as disclosed herein may have a formula selected from: frm-M(CF 3 )-Ile-Phe-Leu-Peg12-NH-(CH 2 ) 2 -Y, frm-M(CF 3 )-Leu-Phe-Peg12-NH-(CH 2 ) 2 -Y, frm-M(CF 3 )-Dpg-2Nal-αMeF-Nle-γE-Peg12-NH-(CH 2 ) 2 -Y, frm-M(CF 3 )-Dpg-2Nal-αMeF-D-Nle-γE-Peg12-NH-(CH 2 ) 2 -Y, frm-M(CF 3 )-Dpg-2Nal-αMeF-Nle-γE-Peg6-γE-γE-Peg6-NH-(CH 2 ) 2 -Y, frm-M(CF 3 )-Dpg-2Nal-αMeF-Nle-γE-Peg6-εK-εK-Peg6-NH-(CH 2 ) 2 -Y, frm-M(CF 3 )-Dpg-2Nal-αMeF-D-Nle-γE-Peg12-NH-(CH 2 ) 2 -Y frm-M(CF 3 )-Dpg-2Nal-αMeF-γE-Peg12-NH-(CH 2 ) 2 -Y, frm-M(CF 3 )-Dpg-4Pal-αMeF-Nle-γE-Peg12-NH-(CH 2 ) 2 -Y, wherein Y comprises an amino group or a cysteine-reactive moiety for conjugating the peptide- linker to the antibody. Suitable cysteine-reactive moieties may include, but are not limited to maleimide, maleimide-diaminopropionic, iodoacetamide, or vinyl sulfone. [00122] In some embodiments of the disclosed conjugates, the linker comprises a maleimide moiety and the linker is conjugated to the antibody or antigen-binding fragment thereof via a thioether bond formed between the maleimide moiety and a cysteine residue of the antibody. [00123] Suitable amino acid residues for conjugating the disclosed peptides and linkers may include cysteine residues. Suitable cysteine residues may be engineered in the antibody or antigen-binding fragment thereof, where the cysteine residues are native cysteine residues of the antibody or antigen-binding fragment thereof or non-native cysteine residues of the antibody of antigen-binding fragment thereof. In some embodiments, the antibody or antigen-binding fragment thereof comprises an IgG heavy chain constant region and light chain region wherein said cysteine residue is selected from residue 124 of the C H 1 domain, residue 378 of the C H 3 domain, or both of residue 124 of the C H 1 domain and residue 378 of the C H 3 domain based on the EU Numbering Index. In some embodiments, the antibody or antigen-binding fragment thereof comprises an IgG heavy chain constant region comprising an isoleucine substituted at residue 247 for cysteine, a glutamic acid substituted at residue 332 for cysteine, or both of an isoleucine substituted at residue 247 for cysteine and a glutamic acid substituted at residue 332 for cysteine based on the EU Numbering Index. In some embodiments, the antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 52, 53, 54, 55, 56, or 57. [00124] Suitable antibodies for the disclosed conjugates and methods may include human antibodies. Other suitable antibodies may include a mouse antibody, a rat antibody, or a rabbit antibody. Suitable therapeutic antibodies may include human antibodies, chimeric or hybrid antibodies, and humanized antibodies. [00125] Suitable antibodies may include IgG isotypes. Suitable IgG isotypes may include isotypes having an IgG heavy chain constant region selected from human IgG1 isotype or human IgG4 isotype. [00126] Suitable antibodies may include monoclonal antibodies. Suitable antibodies may include monospecific antibodies and bispecific antibodies. [00127] The disclosed peptides and optional linkers may be utilized to prepare conjugates of antibodies known in the art or antigen-binding fragments thereof. For example, the disclosed peptides and optional linkers may be conjugated to existing cancer therapeutic antibodies to prepare N-formyl-Met(CF 3 ) peptide-conjugated immunotherapeutics. [00128] Exemplary cancer therapeutics for use in preparing peptide conjugates may include lgG1 therapeutic antibodies targeting solid tumors, including tumors expressing HER-2 (i.e, lgG1 antibodies such as trastuzumab and pertuzumab), liquid tumors, including liquid tumors expressing CD20 (i.e., lgG1 and lgG1-enhanced ADCC antibodies such as rituximab, ofatumumab, obinutuzumab, and AME133v) and antibodies targeting c-Met-expressing tumors (i.e., emibetuzumab). [00129] The N-formyl-Met(CF 3 )-peptides disclosed herein may be conjugated to therapeutic antibodies which comprise cytotoxic agents to function as additional therapeutic agents. Alternatively, the N-formyl-Met(CF 3 )-peptides disclosed herein may replace cytotoxic agents in therapeutic antibodies to create novel therapeutic antibodies that target antigens overexpressed in cancer cells. Target antigens and representative therapeutic antibodies may include, but are not limited to, GPNMB (glembatumumab vedotin), CD56 (lorvotuzumab mertansine (IMGN-901)), TACSTD2 (TROP2; sacituzumab govitecan, (IMMU-132)), CEACAM5 (labetuzumab SN-38), folate receptor-a (mirvetuximab soravtansine (IMGN-853), vintafolide), mucin 1, sialoglycotope CA6; SAR-566658, STEAP1 (vandortuzumab vedotin (RG-7450)), mesothelin (DMOT4039A, anetumab ravtansine (BAY-94-9343), BMS-986148), nectin 4 (enfortumab vedotin (ASG-22M6E); ASC-22CE), ENPP3 (AGS-16M8F), guanylyl cyclase C (indusatumab vedotin (MLN-0264)), SLC44A4 (ASG-5ME), NaPi2b,(lifastuzumab vedotin), CD70 (TNFSF7; DNIB0600A, AMG-172, MDX-1243, vorsetuzumab mafodotin (SGN-75)) CA9 carbonic anhydrase (BAY79-4620), 5T4 (TPBG; PF 06263507) SLTRK6 (ASG-15ME), SC-16 (anti-Fyn3; SC16LD6.5), tissue factor (HuMax-TF-ADC (TF-011- MMAE)), LIV-1 (ZIP6; SGN-LIV1A), P-Cadherin (PCA062) PSMA (MLN2704, PSMA-ADC), Fibronectin Extra-domain B (Human mAb L19 and F8), endothelin receptor ETB (RG-7636), VEGFR2 (CD309; anti-VEGFR-2ScFv-As203-stealth nanoparticles), Tenascin c (anti-TnC-A1 antibody SIP(F16)), periostin (anti-periostin antibody), DLL3 (rovalpituzumab, soravtansine), HER 2 (T-DM1 , ARX788, SYD985), EGFR (ABT-414, IMGN289 AMG-595), CD30 (brentuximab vedotin, iratumumab MDX-060), CD22 (Inotuzumab ozogamicin (CMC-544), pinatuzumab vedotin, epratuzumab SN38), CD79b (polatuzumab vedotin), CD19 (coltuximab ravtansine, SAR-3419, SGN-CD19A), CD138 (indatuximab ravtansine), CD74 (milatuzumab doxorubicin), CD37 (IMGN-529), CD33 (gemtuzumab ozogamicin, IMGN779, SGN CD33 A,) and CD98 (IGN523). (See, e.g., Thomas et al, Lancet Oncol. 2016 Jun; 17(6)e254-62 and Diamantis and Banerji, Brit. Journ. Cancer, 2016; 1 14, 362-367, the content of which is incorporated herein by reference in its entirety). [00130] In some embodiments, the antibodies or antigen-binding fragments thereof of the disclosed conjugates comprise one or more of an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of a known antibody, optionally selected from glembatumumab vedotin, lorvotuzumab mertansine (IMGN-901), TROP2; sacituzumab govitecan, (IMMU-132), labetuzumab SN-38, mirvetuximab soravtansine (IMGN-853), vintafolide, sialoglycotope CA6; SAR-566658, enfortumab vedotin (ASG-22M6E), ASC-22CE), ZIP6, SGN-LIV1A, DMOT4039A, anetumab ravtansine (BAY-94–9343), BMS-986148, sofituzumab vedotin,mirvetuximab soravtansine (IMGN-853), vintafolide, labetuzumab SN-38, glembatumumab vedotin, lorvotuzumab mertansine (IMGN-901), vandortuzumab vedotin (RG- 7450), AGS-16M8F, indusatumab vedotin (MLN-0264), ASG-5ME, lifastuzumab vedotin, TNFSF7, DNIB0600A, AMG-172, MDX-1243, vorsetuzumab mafodotin (SGN-75), BAY79– 4620, TPBG, PF 06263507, SLTRK6 (ASG-15ME), anti-Fyn3, SC16LD6.5), HuMax-TF-ADC (TF-011-MMAE), PCA062, Human mAb L19, Human mAb F8, RG-7636, CD309; anti- VEGFR-2ScFv-As2O3-stealth nanoparticles, anti-TnC-A1 antibody SIP(F16), anti-periostin antibody, rovalpituzumab soravtansine, ABT-414, IMGN289 AMG-595, brentuximab vedotin, iratumumab MDX-060, inotuzumab ozogamicin (CMC-544), pinatuzumab vedotin, epratuzumab SN38, polatuzumab vedotin, coltuximab ravtansine, SAR-3419, SGN-CD19A, indatuximab ravtansine, milatuzumab doxorubicin, IMGN-529, gemtuzumab ozogamicin, IMGN779, SGN CD33 A, and IGN523. [00131] The peptides and conjugates thereof may be formulated as pharmaceutical compositions. In some embodiments, the disclosed pharmaceutical compositions comprise: (i) a conjugated antibody or antigen-fragment thereof, as disclosed herein; and (ii) one or more pharmaceutically acceptable carriers, diluents, or excipients. [00132] The disclosed peptides, conjugates, and pharmaceutical compositions thereof may be utilized in methods of treating diseases and disorders in a subject in need thereof. In some embodiments, the disclosed methods include methods of treating solid cancer or liquid tumors comprising administering to a patient in need thereof an effective amount of a conjugated antibody or a pharmaceutical composition thereof as disclosed herein. Suitable cancers for treating using the disclosed peptides, conjugates, pharmaceutical compositions, and methods may include, but are not limited to, breast cancer, lung cancer, prostate cancer, skin cancer, colorectal cancer, bladder cancer, kidney cancer, liver cancer, thyroid cancer, endometrial cancer, muscle cancer, bone cancer, mesothelial cancer, vascular cancer, fibrous cancer, leukemia, or lymphoma. [00133] The disclosed peptides, conjugates, and pharmaceutical compositions may be utilized for therapy of a subject in need thereof. In some embodiments, the disclosed peptides, conjugates, and pharmaceutical compositions may be uses in the treatment of solid cancers or liquid tumors, which optionally are selected from breast cancer, lung cancer, prostate cancer, skin cancer, colorectal cancer, bladder cancer, kidney cancer, liver cancer, thyroid cancer, endometrial cancer, muscle cancer, bone cancer, mesothelial cancer, vascular cancer, fibrous cancer, leukemia or lymphoma. [00134] Also disclosed herein are methods for activating neutrophils and in particular, for stimulating reactive oxygen species (ROS) production in neutrophils in vivo or in vitro. The methods comprise contacting neutrophils with conjugates as disclosed herein under conditions whereby the conjugates stimulate ROS production in neutrophils. In some embodiments, the conjugates comprise a spacer of a suitable length for inducing ROS production in neutrophils. For example, the conjugates may comprise a polyethylene glycol (PEG) spacer of a suitable length (e.g., a PEG spacer comprising at least 12 monomers) for inducing ROS production. [00135] Also disclosed herein are compounds, which may be otherwise referred to herein as peptides. In some embodiments, the compounds have a formula: R-P 1 -P 2 -P 3 -NH-(CH 2 CH 2 O)n-CH 2 CH 2 -Y or a salt thereof, wherein: R is a HC(=O)- P 1 is Met(C(halogen) m where m is 1-3 (e.g., Met(CF 3 ) or Met(CHF 2 ) or Met(CH 2 F); P 2 is 1-6 proteinogenic or non-proteinogenic amino acids bonded to P 1 and to each other via peptide bonds; P 3 is an amino acid comprising a side chain which comprises a -COOH moiety (e.g., glutamic acid or aspartic acid) or a -NH 2 moiety (e.g., lysine), optionally a glutamic acid residue connected through its side-chain gamma carboxyl group or a lysine residue connected through its side-chain epsilon amino group , and P 3 is bonded to P 2 via a peptide bond; n is an integer selected from 3-24; and Y comprises amino or a cysteine reactive moiety, optionally wherein Y is selected from maleimide, maleimide-diaminopropionic, iodoacetamide, or vinyl sulfone. [00136] In other embodiments, the disclosed compounds have a formula: R-P 1 -P 2 -P 3 -NH-(CH 2 CH 2 O)n-CH 2 CH 2 -Y or a salt thereof, wherein: R is a HC(=O)- P 1 is Met or Met(C(halogen) m where m is 1-3 (e.g., Met(CF 3 ) or Met(CHF 2 ) or Met(CH 2 F); P 2 is 1-6 proteinogenic or non-proteinogenic amino acids bonded to P 1 and to each other via peptide bonds; P 3 is an amino acid comprising a side chain which comprises a -COOH moiety (e.g., glutamic acid or aspartic acid) or a -NH2 moiety (e.g., lysine), optionally a glutamic acid residue connected through its side-chain gamma carboxyl group or a lysine residue connected through its side-chain epsilon amino group , and P 3 is bonded to P 2 via a peptide bond; n is an integer selected from 3-24; and Y comprises amino or a cysteine reactive moiety, optionally wherein Y is selected from maleimide, maleimide-diaminopropionic, iodoacetamide, or vinyl sulfone. [00137] The disclosed peptides and conjugates preferably are agonists of one or more members of the family of formyl peptide receptors. Preferably, the disclosed peptides and conjugates are agonists of the formyl peptide receptor 1 (FPR-1). Preferably, the disclosed peptides and conjugates bind to one or more members of the family of formyl peptide receptors. Preferably, the disclosed peptides and conjugates bind to one or more members of the family of formyl peptide receptors present on the surface of neutrophils. Preferably, the disclosed peptides and conjugates bind to one or more members of the family of formyl peptide receptors with a Kd of at least about 10 uM, 1 uM, 100 nM, 50 nM, 10 nM or lower. As such, the disclosed peptides and conjugates may be utilized in methods for agonizing a formyl peptide receptor, the method comprising contacting the formyl peptide receptor with the peptides or conjugates. EXAMPLES [00138] The following examples are illustrative and should not be interpreted to limit the scope of the claimed subject matter. [00139] Formyl-Met(CF3) and PEG Peptides for Preparing Conjugates [00140] Abstract [00141] Native formyl-methionine peptides are subject to oxidation of the sulfur atom of the methionine residue and the formation of methyl-sulfoxide or generation of met(O) in vivo. (See Fig. 1). The oxidation of the sulfur atom of the methionine residue results in a significant reduction in formyl peptide receptor 1 (FPR-1) agonist activity (e.g., by as much as 10×). As such, formyl-trifluoro-methionine-based peptides (i.e., frm-Met(CF 3 )-containing peptides) which are resistant to oxidation were prepared. Also prepared were peptides containing additional non- proteinogenic amino acids and polyethylene linker/spacers. The peptides were tested to determine whether they could function as FPR-1 agonists in order to determine if the peptides are suitable for preparing antibody bioconjugates to promote FPR-1-mediated and targeted cell killing by innate immune cells. [00142] It was observed that the frm-Met(CF 3 )-containing peptides are capable of activating the human formyl peptide receptor on neutrophils (FPR-1), which make them suitable for modifying antibodies and creating antibody conjugates that exhibit FPR-1-mediated and targeted cell killing. The further was observed that the linker length vis-à-vis polyethylene linker is important for inducing radical oxygen species (ROS) production in neutrophils. Finally, it was found that antibodies conjugated to frm-Met(CF 3 )-containing peptides exhibiting a clearance profile similar to non-conjugated antibodies. [00143] Background [00144] Bactabodies are antibody bioconjugates that engage the innate immune system in targeted cell killing. They consist of an antibody targeted to a specific cell that is conjugated to a pathogen associated molecular pattern (PAMP) that can activate innate immune cells to kill the target cell. [00145] Formyl-peptides provide a PAMP that can be conjugated to an antibody to make a bactabody. Two well-characterized formyl peptides are formyl-Met-Leu-Phe (fMLF) and formyl-Met-Ile-Phe-Leu (fMIFL). fMLF and fMIFL are formyl peptide receptor (FPR) agonists, and FPR-1 receptors are activating receptors present on innate immune cells. fMLF is an effective agonist for human FPR-1, while fMIFL is an effective agonist for both human and mouse FPR-1 receptors. [00146] One concern for in vivo activity of formyl-methionine based FPR-1 agonists is that oxidation of the methionine also reduces the activity of frm-Met peptides. (See Fig. 1). Also, although frm-Met peptides with native amino acids work well in vitro, they are rapidly degraded in vivo, presumably by native endopeptidases present on the surface of cells that bear FPR-1 or by circulating endopeptidases. To address metabolic stability, a modified FPR-1 agonist peptide containing non-proteinogenic acids that are stable for in vivo use was created. Finally, although frm-Met peptides function as agonists per se, the present work suggests that the frm-Met peptides must be displayed via a linker for maximum activity. [00147] Described here are peptides having trifluoro modification of the methionine that eliminates the potential for methionine oxidation while retaining FPR-1 agonism. The disclosed peptides also include non-proteinogenic amino acids to inhibit digestion by endopeptidases. The disclosed peptides also include linkers comprising PEG, which the inventors show are important for maximum agonist activity [00148] Results and Observations [00149] Creation of Peptides. As illustrated in Fig. 2, Fig. 3, and Fig. 4, the inventors prepared a panel of peptides having a frm-Met(CF 3 ), non-proteinogenic amino acids, and PEG linkers for in vitro and in vivo activity as agonists of FPR-1. [00150] The synthesis chemistry for frm-Met(CF 3 ) is illustrated in Fig. 5. Fmoc-S-trityl- L-homocysteine (1, 1.695 g, 2.713 mmol) was dissolved DCM (25 mL) and triisopropylsilane (4 mL, 19.5 mmol) followed by TFA (15 mL, 198.4 mmol) were added at 21 ˚C and the reaction mixture was stirred for 1 h. Concentration in vacuo and co-distilled with MeOH to yield (0.973 g, 2.72 mmol). was dissolved in DCM (25 mL) and the solution cooled to -78 ˚C. (1.00 g, 2.94 mmol) dissolved in DCM was added the reaction mixture was stirred at -78 ˚C for 30 min. The reaction mixture was adsorbed on celite and purified via reverse phase chromatography (50% - 70% 0.1% FA in water/acetonitrile) to yield Fmoc-S-trifluoromethyl-L-homocysteine (4, 153 mg, 0.33 mmol, 12.2%). 1 H NMR (500 HMz, DMSO) δ 12.7 (bs, 1H), 7.89 (d, 2H), 7.73- 7.70 (m, 3H), 7.42 (t, 2H), 7.33 (t, 2H), 4.31-4.30 (m, 2H), 4.24-4.23 (m, 1H), 4.12-4.08 (m, 1H), 2.80-2.70 (m, 2H), 2.16-1.95 (m, 2H); 19 F (352 MHz, DMSO) δ -40 (s, 3F); MS [M + +Na] 448; purity 90% based on HPLC-UV (300 nm). [00151] Briefly, FRM-023 and FRM063 comprise the human peptide MIFL and differ only in that FRM-063 comprises frm-Met(CF 3 ) while FRM-023 comprises frm-Met. [00152] Similarly, FRM-050 and FRM-054 comprise the mouse peptide MFL and differ only in that FRM-054 comprises frm-Met(CF 3 ), while FRM-50 comprises frm-Met. [00153] FRM-052 represents the oxidized control peptide. [00154] FRM-059 represents a frm-Met(CF 3 ) derivative of FRM-047. [00155] FRM-055 represents a D-Nle derivative of FRM-047. [00156] FRM-060 and FRM-061 include two "split" PEG6 linkers in order to reduce flexibility of the PEG12 linker present in FRM-059. [00157] FRM-041 and FRM-051 are versions of FRM-023 and FRM-050, respectively, having a terminal maleimide. [00158] FRM-053 is a version of FRM-052 having a terminal maleimide. [00159] FRM-058 is a version of FRM-055 having a terminal maleimide. [00160] FRM-048 and FRM-049 are branched versions of FRM-047 comprising two peptides and either lacking a terminal maleimide (FRM-048) or having a terminal maleimide (FRM-049). [00161] FRM-057 is a derivative of FRM-047 having an N-terminal methoxinine residue (i.e., methionine in which the sulfur atom is replaced with an oxygen atom). [00162] FRM-056 is a derivative of FRM-047 having a frm-Met(CF 3 ) and lacking a Nle. [00163] FRM-062 is a derivative of FRM-047 having a frm-Met(CF 3 ) and a 4-Pal. [00164] In vitro. C-Terminal Pegylation of frm-Met peptides and frm-Met(CF 3 ) peptides enhances FPR-1 mediated reactive oxygen species (ROS) production from primary human neutrophils. As illustrated in Fig. 6 and Fig. 9, C-terminal pegylation of frm-Met peptides and frm-Met(CF 3 ) peptides enhanced activity for ROS production in neutrophils. ROS production from primary human neutrophils also was enhanced with frm-Met(CF 3 ) peptides having non- proteinogenic amino acids (plus PEG) compared to frm-Met(CF 3 ) peptides with proteinogenic amino acids (plus PEG). [00165] As illustrated in Fig. 8, migration of primary human neutrophils was similar between frm-Met peptides with proteinogenic amino acids (MLF plus PEG) and frm-Met(CF 3 ) peptides with proteinogenic amino acids (frm-M(CF 3 )LF plus PEG). [00166] The inventors also tested conjugated peptides. As illustrated in Fig. 9, ROS production from primary human neutrophils by peptides conjugated to specific eCys sites on trastuzumab by maleimide requires a linker/spacer (e.g., a PEG linker/spacer). frm-Met peptides conjugated to trastuzumab and lacking a spacer were incapable of stimulating ROS production from human neutrophils. [00167] In vivo. Trastuzumab bactabodies with frm-Met peptides and non-proteinogenic amino acids clear faster than trastuzumab parent antibody, resulting in lower exposure with bactabody. As illustrated in Fig.10A versus Fig.10B (and Fig.10C and Fig.10D), conjugating peptide FRM-047 resulted in higher clearance for conjugated antibody versus the non- conjugated parent antibody. Estimated exposure based on AUC0-∞ show 3.8-fold greater exposure for Tmab parent compared to Tmab bactabody with FRM-047 peptide. However, clearance was similar to parent trastuzumab when trastuzumab (Tmab) was conjugated to peptide FRM-058, which is a derivative of peptide FRM-047 having a frm-Met(CF 3 ) moiety. (See Fig. 11). Thus, trifluoro substitution on frm-Met(CF 3 ) the trastuzumab bactabody provides reduced clearance versus the equivalent bactabody with the frm-Met peptide and clearance is similar to the Tmab parent antibody. [00168] Methods [00169] ROS Production. Human neutrophils were purified from fresh blood draws as previously described. Production of reactive oxygen species by primary human neutrophils was measured using luminol-amplified chemiluminescence. Following isolation, PMNs were suspended at 1 x 10 6 cells/ml in HBSS containing calcium and magnesium (Gibco #14025-092) supplemented with 0.25% human serum albumin (Gemini Bio products #800-120) and 50 µM Luminol (Sigma-Aldrich #123072-2.5G). 100 µl of cell suspension (1 x 10 5 total cells) was then distributed into each well of a 96-well plate suitable for fluorescence measurement (Greiner #655098) and temperature equilibrated to 37 o C for 5 minutes. Following equilibration, 10x solutions of agonists were applied to the wells, achieving a 1x final concentration. Immediately after the addition of agonists, chemiluminescence signal was recorded by luminometer. Area under the curve (AUC) scores were calculated using luminescence signal from the first 5 minutes of each run. Values are displayed relative luminescence units. [00170] Chemotaxis. Neutrophil chemotaxis across transwell membranes (Corning #3415) towards agonists in a modified Boyden chamber assay was measured. Approximately 2- 4 x 10 5 cells from neutrophil-enriched preparations were seeded in upper transwell chambers on membranes with 3.0 m pores. The lower transwell chambers contained buffer with or without test agents. Following seeding in transwells, cells were placed at 37º C in a humidified incubator. After one hour any cells in the upper chamber were removed, and the percentage of cells which successfully migrated to the lower chamber was quantified using CellTiter-Glo tm (Promega #G7571) according to manufacturer specified protocol. Percent of successful migration relative to maximal cell-input values were determined using standard curves. Values are displayed as percent of starting cell-input. The U-shaped dose response curve is anticipated. Migration from upper to lower chamber requires a concentration gradient, and as concentration of peptide increases, enhanced diffusion of peptide into the upper chamber leads to deterioration of the concentration gradient necessary to drive migration from upper to lower chamber. [00171] Conclusion [00172] Pegylation of frm-Met peptides and frm-Met(CF 3 ) peptides enhances FPR-1 mediated reactive oxygen species (ROS) production from primary human neutrophils. frm- Met(CF 3 ) peptides with non-proteinogenic amino acids are more effective than frm-Met(CF 3 ) peptides with native amino acids at driving FPR-1 mediated ROS production from primary human neutrophils [00173] In the foregoing description, it will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention. Thus, it should be understood that although the present invention has been illustrated by specific embodiments and optional features, modification and/or variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention. [00174] Citations to a number of patent and non-patent references may be made herein. The cited references are incorporated by reference herein in their entireties. In the event that there is an inconsistency between a definition of a term in the specification as compared to a definition of the term in a cited reference, the term should be interpreted based on the definition in the specification. [00175] Certain embodiments are below, numbered 1-53: [00176] (1) A conjugated antibody or antigen-binding fragment thereof comprising an antibody or an antigen-binding fragment thereof that is conjugated to a peptide comprising an N- formyl-halogenated methionine residue at the N-terminus of the peptide. [00177] (2) The conjugated antibody of embodiment 1, wherein the N-formyl-halogenated methionine residue is N-formyl-trifluorinated methionine. [00178] (3) The conjugated antibody of embodiment 1 or 2, wherein the antibody is conjugated to the peptide via a linker. [00179] (4) The conjugated antibody of any of the foregoing embodiments, wherein the conjugated antibody has a formula represented as: [00180] (5) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises a C-terminal glutamic acid residue and the peptide is conjugated to the linker via an amide bond formed between the gamma carboxyl group of the glutamic acid and an amino group of the linker. [00181] (6) The conjugated antibody of any of embodiments 1-5, wherein the peptide comprises a C-terminal lysine residue and the peptide is conjugated to the linker via an amide bond formed between the epsilon amino group of the lysine and a carboxyl group of the linker. [00182] (7) The conjugated antibody of any of the foregoing embodiments, wherein the conjugated antibody has a formula represented as: [00183] (8) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids and include a halogen-substituted amino acid (e.g., N-formyl-trifluorinated methionine at the N- terminus). [00184] (9) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids selected from D-amino acids (e.g., D-amino acids of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine). [00185] (10) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids selected from homologues of amino acids lacking one or more methylene groups between the α- carbon and the side chain or homologous of amino acids possessing an additional methylene group between the α -carbon and the side chain (e.g., homo-amino acids, bishomo-amino acids, and the like). [00186] (11) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids selected from homologues of amino acids lacking one or more methylene groups between the α- carbon and the side chain (e.g., 2-aminoisobutyric acid, 2-amino-2-hydroxyacetic acid, 2α- methyl-2-hydroxy-glycine, 2-amino-2-methylbutyric acid (i.e., isovaline), methylcysteine, azetidine-2-carboxylic acid, phenylglycine, 4-hydroxyphenylglycine, 3-indolylglycine, aminomalonic acid, 2,3-diamino-3-oxopropanoic acid, 2-amino-2-(1H-imidazol-5-yl)acetic acid, ornithine, 2,4-diaminobutanoic acid, 2,3-diaminopropionic acid, and 2-amino-4- (diaminomethylideneamino)butanoic acid). [00187] (12) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids selected from homo-amino acids (e.g., homo-amino acids of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine, such as homo-alanine, homo-arginine, homo-glutamine, homo-glutamic acid, homo-isoleucine, homo- leucine, homo-lysine, homo-methionine, homo-phenylalanine, homo-proline (i.e., piperidine-2- carboxylic acid), homo-serine, homo-threonine, homo-tryptophan, and homo-tyrosine). [00188] (13) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids selected from bishomo-amino acids (e.g., bishomo-amino acids of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine). [00189] (14) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids selected from alkylated amino acids comprising an alkyl substitution (e.g., a C 1 -C 6 alkyl substitution) on the α-carbon (e.g., α-carbon, alkyl substituted alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine, such as 2- methyl-serine (i.e., α-methyl-serine), 2-methyl-threonine (i.e., α-methyl-threonine), α-methyl- valine, α-methyl-leucine, 2-amino-2,3-dimethyl-pentanoic acid (i.e., α-methyl-isoleucine), α- methyl-methionine, α-methyl-cysteine, 2-methyl-proline, α-methyl-phenylalanine, α-methyl- tyrosine, α-methyl-tryptophan, 2-methyl-aspartic acid, 2-methyl-glutamic acid, 2,4-diamino-2- methyl-4-oxobutanoic acid (i.e., α-methyl-asparagine), 2,5-diamino-2-methyl-5-oxopentanoic acid (i.e., α-methyl-glutamine), α-methyl-histidine, α-methyl-lysine, and 2-methyl-arginine (i.e., α-methyl-lysine)). [00190] (15) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids selected from di-alkylated amino acids comprising a di-alkyl substitution (e.g., a C 1 -C 6 alkyl substitution) on the α-carbon (e.g., α-carbon, di-alkyl substituted glycine, such as dipropylglycine (Dpg)). [00191] (16) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids selected from alkylated amino acids comprising an alkyl substitution (e.g., a C 1 -C 6 alkyl substitution) on the amino group (e.g., N-alkylated alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine, such as N-methyl- alanine, N-methyl-arginine, N-methyl-asparagine, N-methyl-aspartic acid, N-methyl-cysteine, N-methyl-glutamic acid, N-methyl-glutamine, N-methyl-glycine, N-methyl-histidine, N-methyl- isoleucine, N-methyl-leucine, N-methyl-lysine, N-methyl-methionine, N-methyl-phenylalanine, N-methyl-proline, N-methyl-serine, N-methyl-threonine, N-methyl-tryptophan, N-methyl- tyrosine, and N-methyl-valine. [00192] (17) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids selected from phenylalanine, tyrosine, tryptophan, histidine, proline, naphthylalanine, optionally comprising one or more ring-substitutions selected from C 1 -C 6 alkyl substitutions, halogen- substitutions, and cyano-substitutions (e.g., 2-fluoro-phenylalanine, 2-methyl-tyrosine, and 2- naphthylalanine). [00193] (18) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids selected from nor-amino acids and/or linear core amino acids such as norleucine (Nle), norvaline (Nva), 12-amino-dodecanoic acid, 8-amino-caprylic acid, 7-amino-enanthic acid, 6-amino- carpoic acid, and 5-amino-pentanoic acid. [00194] (19) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids selected from amino acids (e.g., alanine) comprising a substitution selected from alkynyl (e.g., propargylglycine), azido (e.g., 4-azido-homo-alanine), thiophenyl, thienyl, (e.g., 3-(2-thineyl)- alanine), pyridyl (e.g., 3-(4-pyridyl-alanine (4-Pal)), anthrenyl, cycloalkyl, diphenyl, furyl, and naphthyl. [00195] (20) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids selected from amino acids having a formula NH 2 -CH 2 -CH 2 -(O-CH 2 -CH 2 ) n -COOH, wherein n is selected from 1-24. [00196] (21) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids selected from β-amino acids, γ-amino acids, δ-amino acids, ε-amino acids, and ζ-amino acids (e.g., β-, γ-, δ, ε-, and ζ-amino acids of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine). [00197] (22) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises 2-10 amino acids, which optionally are non-proteinogenic amino acids selected from cycloamino acids (e.g., aziridine-2-carboxylic acid, azetidine-2-carboxylic acid, piperidine-2-carboxylic acid, azepane-2-carboxylic acid, cycloleucine, homocycloleucine, 1- piperidine-4-carboxylic acid, piperidine-3-carboxylic acid, 1-piperazineacetic acid, 4- piperidineacetic acid, and 1-piperidineacetic acid). [00198] (23) The conjugated antibody of any of the foregoing embodiments, wherein the peptide comprises an amino-protecting group (-N- optionally selected from allyloxycarbonyl (Alloc), 9-fluorenylmethyl carbonyl (Fmoc), t-butyl carbonyl (BOC), and benzyl carbonyl (Cbz). [00199] (24) The conjugated antibody of any of the foregoing embodiments, wherein the linker comprises a spacer arm having a length of about 10-50 angstroms (or 10-40 angstroms, or 10-30 angstroms, or 10-20 angstroms). [00200] (25) The conjugated antibody of any of the foregoing embodiments, wherein the linker comprises a spacer arm and the linker has a formula selected from:
[00201] (26) The conjugated antibody of embodiment 24 or 25, wherein the linker has a formula selected from
where n is an integer selected from 3-24. [00202] (27) The conjugated antibody of embodiment 24 or 25, wherein the spacer arm is a peptide sequence comprising amino acids selected from glycine, serine, and alanine (e.g., (G 4 S) m where m is an integer selected from 1-5). [00203] (28) The conjugated antibody of any of the foregoing embodiments, wherein the linker comprises a polyethylene glycol (Peg) moiety (i.e., (-O-CH2-CH2) 1-24 ). [00204] (29) The conjugated antibody of any of the foregoing embodiments, wherein the linker comprises a split polyethylene glycol moiety represented as -((Peg) 1-24 )-(AA) 1-2 -((Peg) 1- 24)-, wherein AA is Glutamic acid residue connected through its side-chain gamma carboxyl group or Lysine residue connected through its side-chain epsilon amino group. [00205] (30) The conjugated antibody of any of the foregoing embodiments, wherein the peptide-linker has a formula selected from: frm-M(CF 3 )-Ile-Phe-Leu-Peg12-NH-(CH 2 ) 2 -Y, frm- M(CF 3 )-Leu-Phe-Peg12-NH-(CH 2 ) 2 -Y, frm-M(CF 3 )-Dpg-2Nal-αMeF-Nle-γE-Peg12-NH- (CH 2 ) 2 -Y, frm-M(CF 3 )-Dpg-2Nal-αMeF-D-Nle-γE-Peg12-NH-(CH 2 ) 2 -Y, frm-M(CF 3 )-Dpg- 2Nal-αMeF-Nle-γE-Peg6-γE-γE-Peg6-NH-(CH 2 ) 2 -Y, frm-M(CF 3 )-Dpg-2Nal-αMeF-Nle-γE- Peg6-εK-εK-Peg6-NH-(CH 2 ) 2 -Y, frm-M(CF 3 )-Dpg-2Nal-αMeF-D-Nle-γE-Peg12-NH-(CH 2 ) 2 -Y, frm-M(CF 3 )-Dpg-2Nal-αMeF-γE-Peg12-NH-(CH 2 ) 2 -Y, and frm-M(CF 3 )-Dpg-4Pal-αMeF-Nle- γE-Peg12-NH-(CH 2 ) 2 -Y, wherein Y comprises an amino group or a cysteine-reactive moiety for conjugating the peptide-linker to the antibody. [00206] (31) The conjugated antibody of embodiment 30, wherein the cysteine-reactive moiety is selected from maleimide, maleimide-diaminopropionic, iodoacetamide, or vinyl sulfone. [00207] (32) The conjugated antibody of any of the foregoing embodiments, wherein the linker comprises a maleimide moiety and the linker is conjugated to the antibody via a thioether bond formed between the maleimide moiety and a cysteine residue of the antibody. [00208] (33) The conjugated antibody of embodiment 32, wherein the antibody comprises an IgG heavy chain constant region and light chain region wherein said cysteine residue is selected from residue 124 of the C H 1 domain, residue 378 of the C H 3 domain, or both of residue 124 of the C H 1 domain and residue 378 of the C H 3 domain. [00209] (34) The conjugated antibody of any of the foregoing embodiments, wherein the antibody is a human antibody, a chimeric or hybrid antibody, or a humanized antibody. [00210] (35) The conjugated antibody of any of the foregoing embodiments, wherein the antibody comprises an IgG heavy chain constant region selected from human IgG1 isotype or human IgG4 isotype. [00211] (36) The conjugated antibody of any of the foregoing embodiments, wherein the antibody comprises an IgG heavy chain constant region comprising an isoleucine substituted at residue 247, a glutamic acid substituted at residue 332, or both of an isoleucine substituted at residue 247 and a glutamic acid substituted at residue 332, with numbering based on EU Index Numbering. [00212] (37) The conjugated antibody of any of the foregoing embodiments, wherein the antibody comprises a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 52, 53, 54, 55, 56, or 57. [00213] (38) The conjugated antibody of any of the foregoing embodiments, wherein the antibody is a monoclonal antibody. [00214] (39) The conjugated antibody of any of the foregoing embodiments, wherein the antibody is a bispecific antibody. [00215] (40) The conjugated antibody of any of the foregoing embodiments, wherein the antibody binds to an antigen selected from HER2, PSMA, TROP2, MUC-1, Nectin 4, LIV-1, mesothelin, MUC-16, folate receptor-R1, CEACAM5, GPNMB, CD56, STEAP1, ENPP3, guanylyl cyclase C, SLC44A4, NaPi2b, CD70, CA9 carbonic anhydrase, 5T4, SC-16, tissue factor, P-Cadherin, Fibronectin Extra-domain B, endothelin receptor ETB, VEGFR2, Tenascin c, periostin, DLL3, EGFR, CD30, CD22, CD79b, CD19, CD138, CD74, CD37, CD33, and CD98. [00216] (41) The conjugated antibody of any of the foregoing embodiments, wherein the antibody comprises one or more of an HCDR1, an HCDR2, an HCDR3, an LCDR1, an LCDR2, and an LCDR3 of an antibody selected from T-DM1, ARX788, SYD985, MLN2704, PSMA- ADC, TACSTD2, sacituzumab govitecan, (IMMU-132)), mucin 1, sialoglycotope CA6; SAR- 566658, enfortumab vedotin (ASG-22M6E), ASC-22CE), ZIP6, SGN-LIV1A, DMOT4039A, anetumab ravtansine (BAY-94–9343), BMS-986148), sofituzumab vedotin, mirvetuximab soravtansine (IMGN-853), vintafolide, labetuzumab SN-38, glembatumumab vedotin, lorvotuzumab mertansine (IMGN-901), vandortuzumab vedotin (RG-7450), AGS-16M8F, indusatumab vedotin (MLN-0264), ASG-5ME, lifastuzumab vedotin, TNFSF7, DNIB0600A, AMG-172, MDX-1243, vorsetuzumab mafodotin (SGN-75), BAY79–4620, TPBG, PF 06263507, SLTRK6 (ASG-15ME), anti-Fyn3, SC16LD6.5), HuMax-TF-ADC (TF-011- MMAE), PCA062, Human mAb L19 and F8, RG-7636, CD309; anti-VEGFR-2ScFv-As2O3- stealth nanoparticles, anti-TnC-A1 antibody SIP(F16), anti-periostin antibody, rovalpituzumab soravtansine, ABT-414, IMGN289 AMG-595, brentuximab vedotin, iratumumab MDX-060, inotuzumab ozogamicin (CMC-544), pinatuzumab vedotin, epratuzumab SN38, polatuzumab vedotin, coltuximab ravtansine, SAR-3419, SGN-CD19A, indatuximab ravtansine, milatuzumab doxorubicin, IMGN-529, gemtuzumab ozogamicin, IMGN779, SGN CD33 A, and IGN523. [00217] (42) A pharmaceutical composition comprising the conjugated antibody of any of the foregoing embodiments and one or more pharmaceutically acceptable carriers, diluents, or excipients. [00218] (43) A method of treating solid cancer or liquid tumors comprising administering to a patient in need thereof an effective amount of a conjugated antibody, as recited in any of embodiments 1-41, or a pharmaceutical composition thereof, as recited in embodiment 42. [00219] (44) The method of embodiment 43 for treating breast cancer, lung cancer, prostate cancer, skin cancer, colorectal cancer, bladder cancer, kidney cancer, liver cancer, thyroid cancer, endometrial cancer, muscle cancer, bone cancer, mesothelial cancer, vascular cancer, fibrous cancer, leukemia, or lymphoma. [00220] (45) The conjugated antibody of any of embodiments 1-41for use in therapy. [00221] (46) The conjugated antibody of any of embodiments 1-41 use in the treatment of solid cancers or liquid tumors. [00222] (47) The conjugated antibody of embodiment 46 for use in the treatment of breast cancer, lung cancer, prostate cancer, skin cancer, colorectal cancer, bladder cancer, kidney cancer, liver cancer, thyroid cancer, endometrial cancer, muscle cancer, bone cancer, mesothelial cancer, vascular cancer, fibrous cancer, leukemia or lymphoma. [00223] (48) Use of the antibody of any of embodiments 1-47 for manufacturing a medicament for the treatment of solid cancers or liquid tumors. [00224] (49) The use of embodiment 48, wherein the solid cancers or liquid tumors are selected from breast cancer, lung cancer, prostate cancer, skin cancer, colorectal cancer, bladder cancer, kidney cancer, liver cancer, thyroid cancer, endometrial cancer, muscle cancer, bone cancer, mesothelial cancer, vascular cancer, fibrous cancer, leukemia, or lymphoma. [00225] (50) A method for stimulating reactive oxygen species (ROS) production in a neutrophil, the method comprising contacting the neutrophil with the conjugated antibody of any of embodiments 1-41 under conditions whereby the conjugated antibody stimulates ROS production in the neutrophil. [00226] (51) The method of embodiment 48, wherein the linker of the conjugated antibody comprises a polyethylene glycol spacer comprising at least 12 monomers. [00227] (52) A compound having a formula R-P 1 -P 2 -P 3 -NH-(CH 2 CH 2 O) n -CH 2 CH 2 -Y or a salt thereof, wherein: R is a HC(=O)-; P 1 is Met(C(halogen) m where m is 1-3 (e.g., Met(CF 3 ) or Met(CHF2) or Met(CH 2 F); P 2 is 1-6 proteinogenic or non-proteinogenic amino acids bonded to P 1 and to each other via peptide bonds; P 3 is an amino acid comprising a side chain which comprises a -COOH moiety (e.g., glutamic acid or aspartic acid) or a -NH 2 moiety (e.g., lysine), optionally a glutamic acid residue connected through its side-chain gamma carboxyl group or a lysine residue connected through its side-chain epsilon amino group , and P 3 is bonded to P 2 via a peptide bond; n is an integer selected from 3-24; and Y comprises amino or a cysteine reactive moiety, optionally wherein Y is selected from maleimide, maleimide-diaminopropionic, iodoacetamide, or vinyl sulfone. [00228] (53) A compound having a formula R-P 1 -P 2 -P 3 -NH-(CH 2 CH 2 O) n -CH 2 CH 2 -Y or a salt thereof, wherein: R is a HC(=O)- ; P 1 is Met or Met(C(halogen) m where m is 1-3 (e.g., Met(CF 3 ) or Met(CHF2) or Met(CH 2 F); P 2 is 1-6 proteinogenic or non-proteinogenic amino acids bonded to P 1 and to each other via peptide bonds; P 3 is an amino acid comprising a side chain which comprises a -COOH moiety (e.g., glutamic acid or aspartic acid) or a -NH 2 moiety Ĩe.g., lysine), optionally a glutamic acid residue connected through its side-chain gamma carboxyl group or a lysine residue connected through its side-chain epsilon amino group , and P 3 is bonded to P 2 via a peptide bond; n is an integer selected from 3-24; and Y comprises amino or a cysteine reactive moiety, optionally wherein Y is selected from maleimide, maleimide- diaminopropionic, iodoacetamide, or vinyl sulfone.